Genentech to Present New Data Demonstrating the Breadth and Depth of Its Alzheimer’s Program at the Upcoming Alzheimer's Association International Conference (AAIC)

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that it will present 16 new data presentations across its Alzheimer’s disease (AD) pipeline at this year’s Alzheimer's Association International Conference (AAIC) from July 22-26 in Chicago, Illinois. Roche and Genentech’s AD pipeline includes two late-stage investigational molecules, crenezumab and gantenerumab, which are both in Phase III clinical trials, and an anti-tau molecule in Phase II.

“The range of data that Roche and Genentech are presenting at AAIC is a testament to our commitment to bring new treatments to help the many millions of people living with Alzheimer’s disease,” said Sandra Horning, M.D., chief medical officer and head of Global Product Development.

In a late-breaking session, an exploratory analysis is being presented on crenezumab from the completed Phase II BLAZE and ABBY clinical trials that will show the impact of crenezumab treatment over the whole trial duration on beta amyloid oligomer levels in cerebrospinal fluid (CSF) in people with mild to moderate AD. Baseline data from the CREAD 1 study in prodromal to mild AD will also be presented. Crenezumab is an investigational, monoclonal antibody designed to preferentially bind to and promote removal of oligomers, a form of beta amyloid.

Additionally, updates from open-label extension studies of gantenerumab, including data on the effects of higher doses of gantenerumab in reducing amyloid PET load at 24 months, as well as long-term safety data, will be presented. Data on the effects of low doses of gantenerumab on amyloid and tau biomarkers in CSF will also be presented. Gantenerumab is an investigational, monoclonal antibody designed to bind to aggregated beta amyloid and remove beta amyloid plaques. Two recently initiated Phase III GRADUATE clinical studies are evaluating the safety and efficacy of gantenerumab for the treatment of early AD.

The full range of data from Roche and Genentech’s Alzheimer’s clinical development program, including investigational medicines and diagnostics, being presented at AAIC include:

Investigational Medicine		Abstract Title		Abstract Number (type), Presentation Date, Time
Crenezumab		LATE BREAKER: Target Engagement in an AD Trial: Crenezumab Lowers Aβ Oligomer Levels in CSF